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A micellar formulation of amphotericin B (AmB) solubilized with poloxamer 188 was evaluated against an
AmB Leishmania donovani-resistant line. A concave isobologram showed a synergistic effect of this association
against promastigotes. This result was confirmed with amastigotes since the 50% effective concentration of the
new formulation was 100 times less than that of the control AmB formulation.
The use of amphotericin B (AmB) for the treatment of
visceral leishmaniasis (VL) is increasing as a consequence of
the worldwide spread of resistance to the first-line pentavalent
antimonials (7) and the improvement of the therapeutic index
of AmB in the commercialized lipidic formulations (AmBi-
some, Amphocil, and Albecet). Clinical trials have indicated
that these formulations decrease the toxicity of the drug and
that they are also more active against this parasite (3, 4, 5, 8, 9,
10, 17, 22, 24).
Since AmB is increasingly used, the risk of the appearance of
clinical resistance could increase. In anticipation of this fact, a
line of AmB-resistant (AmBr) Leishmania donovani promas-
tigotes was established by stepwise drug pressure (16), and
their biological properties were compared with those of the
wild-type (WT) parent strain. Ergosterol, the main target of
AmB in fungi, was present in the membranes of WT strains but
was not found in the membranes of the AmB-resistant line of
isolates (16). This modification was accompanied by an in-
crease in membrane fragility and fluidity. The AmB-resistant
promastigotes were infective for macrophages in vitro, but
their virulence was considerably decreased in vivo. Strategies
that can be used to overcome the resistance should be inves-
tigated.
In a previous work (11), we studied the physicochemical
properties of a formulation of AmB solubilized with poloxamer
188. Poloxamers are water-soluble, nonionic, triblock copoly-
meric surfactants of poly(ethylene oxide) and poly(propylene
oxide) (20). Among them, poloxamer 188 was approved by the
Food and Drug Administration as a safe ingredient for injec-
tions (1), and it is reported in the National Formulary as a
pharmaceutical ingredient (23). These formulations were less
toxic to red blood cells, macrophages, and renal cells and were
also less toxic in vivo in noninfected mice (M. S. Espuelas, P.
Legrand, P. Loiseau, C. Bories, C. Gamazo, J.-P. Devissaguet,
M. J. Renedo, and J. M. Irache, Proc. 1st World Meet. APGI/
APV on Pharmaceutics, Biopharmaceutics and Pharmaceuti-
cal Technol. p. 569–570, 1998).
The sizes of AmB aggregates decreased and the degree of
AmB self-aggregation increased with the poloxamer concen-
tration used to solubilize the drug. As Mullen et al. (19) re-
ported a correlation between the degree of AmB aggregation
in the lipidic formulations and their antileishmanial activities,
in the present study, the antileishmanial activity of the micellar
formulation of AmB solubilized with poloxamer 188 at two
different concentrations was assessed in vitro against both
WT and AmBr L. donovani DD8 (strain MHOM/IN/80/DD8)
promastigotes and intramacrophagic amastigotes. Amastigotes
were maintained in golden hamsters. The parasites were har-
vested from an infected spleen for the assays.
A stock solution of AmB aqueous dispersion used as a con-
trol was prepared by solubilization of AmB powder (Bristol-
Myers Squibb, Barcelona, Spain) in dimethyl sulfoxide (DMSO)
at a concentration of 10 mg/ml followed by dispersion of this
organic stock solution in water to obtain a concentration of 1
mg/ml (AmB-DMSO). The micellar formulation of the drug
with a low poloxamer 188 concentration (12.5 mg/ml; AmB-
MM[12.5]) and a high poloxamer 188 concentration (125 mg/
ml; AmB-MM[125]) was prepared as described previously (11).
Peritoneal macrophages were harvested from female CD1
mice (Charles River) 3 days after injection of sodium thiogly-
colate (Biome´rieux) and were dispensed into eight-well cham-
ber slides (LabTek Ltd.) at a concentration of 5 3 104/well
(400 ml/well) in RPMI 1640 medium (Gibco BRL) supple-
mented with 10% heat-inactivated fetal calf serum (FCS)
(Gibco BRL) and 2 mM L-glutamine. After 24 h, the macro-
phages were infected with WT amastigotes at a ratio of 10
parasites per macrophage. In the case of AmBr amastigotes, a
ratio of 20 parasites per macrophage was required to obtain
similar percentages of infected macrophages (about 80%) and
similar mean numbers of amastigote per macrophage (10
amastigotes per macrophage). After 24 h of incubation, the
infected macrophages were exposed to different AmB formu-
lations at concentrations that ranged from 0.001 to 1 mg/ml for
WT parasites and 0.001 to 10 mg/ml for AmBr parasites. After
2 days, the percentage of infected macrophages was evaluated
microscopically after Giemsa staining (Table 1). The 50% ef-
fective doses (EC50s) were determined by linear regression
analysis with 95% confidence limits. As shown in Table 1, when
the highest poloxamer concentration was used to solubilize
AmB (AmB-MM[125]), the activity against AmBr parasites
was increased 100 times compared to that of AmB-DMSO,
whereas poloxamer 188 alone had no significant effect.
Two main hypotheses were tested to explain this reversion of
resistance. The first one relies on the fact that poloxamers are
described to have direct effects on macrophage activation (20),
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and this possibility may be involved in the increase in the
antileishmanial activity (6). The level of nitrous oxide (NO)
production and the tumor necrosis factor alpha (TNF-a) ac-
tivity in the medium were determined. The amount of NO
produced was measured spectrophotometrically at 540 nm
(Labsystem microplate reader), and TNF-a activity was deter-
mined by a cytotoxicity assay with L929 cells as described
previously (12). Table 2 shows that the formulation of AmB
solubilized with poloxamer 188 did not stimulate macrophages.
Furthermore, these formulations seemed to inhibit NO pro-
duction caused by dependent effector mechanisms (TNF-a
production) induced by administration of free drug in the
presence of gamma interferon (20 IU/ml; Genzyme) as a co-
stimulus (18).
As a consequence, the antileishmanial activity of the micel-
lar formulation of AmB solubilized with poloxamer 188 would
principally be the result of a direct action of the drug and/or
the poloxamer on the parasite membrane. To check this hy-
pothesis, the possibility of synergy between AmB and polox-
amer 188 was studied with the promastigote form of the par-
asite. Synergism between nonionic surfactants (i.e., Triton
WR139 or poloxamers CRL8131 and CRL8142) and antibiot-
ics (isoniazide or clindamycin) against other intramacrophage
pathogens such as Mycobacterium (14) or Toxoplasma gondii
has already been reported (2). However, in all cases, these
surfactants were more hydrophobic than the poloxamer 188
used in the present study. On the other hand, only one example
of synergism between AmB and a surfactant has been reported
in vitro with alkyl glycerol ethers against fungi (13). In this
work, promastigotes from a logarithmic-phase culture were
used at 2 3 105 cells per well in 96-well microplates (Nunclon)
in RPMI 1640 medium supplemented with 20% FCS. Different
concentrations of AmB and/or poloxamer 188 were added to
the same medium. After a 48-h incubation period for WT
parasites and a 72-h incubation period for AmBr parasites, cell
viability was evaluated by a colorimetric assay for mitochon-
drial oxidative activity with 3-(4,5-dimethylthiazol-2-yl)2,5-
diphenyltetrazolium bromide. An isobologram prepared from
the 50% inhibitory concentrations (IC50s) allowed assessment
of the interactions between AmB and poloxamer 188. For both
lines (WT and AmBr), the activity of poloxamer 188 alone
increased with the concentration (0 to 125 mg/ml). The surfac-
tant at 125 mg/ml killed 30% of the WT promastigotes and
50% of the AmBr promastigotes (data not shown). Poloxamer
188 did not modify the activity of AmB against WT parasites,
as indicated by the planar form of the isobologram (Fig. 1A).
However, against the AmBr line, a concave isobologram indi-
cated synergistic action between AmB and poloxamer 188 (Fig.
1B). We suggest that poloxamer 188 is able to interact only
within the fragile AmBr parasite membranes and promote the
insertion of AmB within them. This could be the reason for the
increase in toxicity exerted by AmB against the AmBr parasite,
even though ergosterol, the main target of AmB, does not exist
in AmBr parasites (21). We must also keep in mind the fact
that if the AmB resistance is due to an overexpression of P
glycoprotein, the poloxamer could inhibit the protein and in-
crease the global absorption of the drug, as reviewed by Kwon
and Okano (15).
The synergistic activity of AmB and poloxamer 188 against
extracellular AmB-resistant promastigotes correlated with the
strickingly increased activity and the reversion of resistance
observed for amastigotes treated with poloxamer 188 and AmB
FIG. 1. Isobolograms of the IC50s obtained with combinations of AmB and
poloxamer 188 against WT (A) and AmBr (B) L. donovani promastigotes.
TABLE 1. In vitro activities of AmB-DMSO and a micellar
formulation of AmB solubilized with poloxamer 188 against WT
and AmBr intramacrophagic amastigotes of L. donovani DD8
Formulation
EC50 (mg/ml)a
WT AmBr
AmB-DMSO 0.083 6 0.009 1.07 6 0.08
AmB-MM[12.5] 0.085 6 0.011 1.01 6 0.13
AmB-MM[125] 0.032 6 0.004b 0.012 6 0.001b
Poloxamer 188 .1,250 .1,250
a Data are the means 6 standard deviations (n 5 3).
b Significant difference (P , 0.05).
TABLE 2. NO and TNF-a production induced by AmB-DMSO
and AmB-MM with AmB at 1 mg/ml combined with gamma
interferon (20 IU/ml) after a 48-h treatment of macrophages
infected with WT and AmBr promastigotes of L. donovani
Formulation
WT AmBr
NO
production
(mM)a
TNF-a
production
(pg/ml)a
NO
production
(mM)a
TNF-a
production
(pg/ml)a
Nontreated control 8.50 6 0.18 6.90 7.55 6 0.84 NDb
AmB-DMSO 16.06 6 2.97 10.61 10.25 6 0.10 10.76
Poloxamer 188 8.50 6 0.26 6.99 ND 5.81
AmB-MM[12.5] 11.41 6 1.71 7.57 6.84 6 0.15 7.20
AmB-MM[125] 10.07 6 0.21 6.26 6.89 6 0.43 6.90
a Data are the means 6 standard deviations of two measurements.
b ND, not determined.
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at a high ratio (AmB-MM[12.5]). The increase in the activity of
AmB against the WT amastigotes, even when poloxamer 188
does not modify the activity of free drug at the membrane
level, could be a consequence of the surfactant’s effect on the
AmB aggregation. This fact may improve drug uptake by mac-
rophages and drug availability for the parasite (19).
As no correlation has been found between the antileishma-
nial activity of AmB-lipid preparations in vitro (free AmB was
four times more active than AmBisome against promastigotes
and amastigotes) and in vivo (AmBisome was more active than
conventional AmB) (24), further in vivo experiments must be
carried out to fully evaluate our formulations. Nevertheless,
this study suggests that the micellar formulation of AmB sol-
ubilized with poloxamer 188 could provide a simple and inex-
pensive way to increase the therapeutic index of AmB in the
treatment of VL. It would also be able to reverse the resistance
of the parasite to this drug if this problem begins to appear in
clinical practice in the future.
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